Sai Parenteral's (NSE:SAIPARENT) Accounts Payable: ₹1,756 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Accounts Payable?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Accounts Payable is ₹1,756 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Accounts Payable for the quarter that ended in Sep. 2025 was ₹1,756 Mil.

Sai Parenteral's's quarterly Accounts Payable increased from Mar. 2024 (₹527 Mil) to Mar. 2025 (₹1,921 Mil) but then declined from Mar. 2025 (₹1,921 Mil) to Sep. 2025 (₹1,756 Mil).

Sai Parenteral's's annual Accounts Payable increased from Mar. 2023 (₹222 Mil) to Mar. 2024 (₹527 Mil) and increased from Mar. 2024 (₹527 Mil) to Mar. 2025 (₹1,921 Mil).

Sai Parenteral's Accounts Payable Related Terms

Sai Parenteral's Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Accounts Payable Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Accounts Payable
222.36 527.43 1,921.41

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Accounts Payable 222.36 527.43 1,921.41 1,756.49
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ₹1,756 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Accounts Payable of ₹1,756 Mil as of Sep. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Accounts Payable too high?
Sai Parenteral's' current Accounts Payable is ₹1,756 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Accounts Payable compare to LLY and JNJ?
Sai Parenteral's' Accounts Payable of ₹1,756 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Accounts Payable is ₹1,756 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Accounts Payable of ₹1,756 Mil. The current Accounts Payable is ₹1,756 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Accounts Payable is ₹1,756 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price